

32ND ANNUAL

New Drugs and Modern Concepts in Pharmacotherapy

15-Hour CE Program

April 17 - 18, 2021

April 24 - 25, 2021

UNIVERSITY OF THE
PACIFIC

Thomas J. Long
School of Pharmacy

Planning Committee

Nancy L. DeGuire, PharmD,
Clinical Professor of Pharmacy Practice and Director for Postgraduate Professional Education, Thomas J. Long School of Pharmacy, University of the Pacific

Julio R. Lopez, PharmD
Retired pharmacist

Linda L. Norton, PharmD,
Professor and Chair, Department of Pharmacy Practice, Thomas J. Long School of Pharmacy, University of the Pacific

Dua Her
Director of External Relations and Professional Development, Thomas J. Long School of Pharmacy, University of the Pacific

Becky Perry
Alumni Relations Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific

In accordance with ACPE policies, all Planning Committee members were required to complete a "Declaration of Disclosure-Conflict of Interest Statement" prior to this educational activity. All have indicated no relationship to disclose relating to the subject matter of these presentations.

Contact Us
pharmacy.pacific.edu
pharmacyce@pacific.edu
209.932.3275

Registration

Register at www.newdrugsce.com

This webinar will be hosted on Zoom. The meeting information will be sent to attendees 48 hours prior to the start of the program. The attendee's Zoom meeting link will be unique to the attendee.

DATE	TYPE	STANDARD PHARMACIST FEE
2/22 - 3/22/2021	EARLY BIRD	\$425
3/22 - 4/22/2021	REGULAR	\$450

Activity Type

This knowledge- and application-based learning activity is designed to provide pharmacists with the most current information regarding new drugs and new indications for older drugs. Lecture topics have been selected to reflect major areas of advancement in clinical therapeutics. The target audience for this program are pharmacists in a variety of settings including outpatient clinical care, managed care, consulting and inpatient-based practice.

Accreditation



The University of the Pacific, Thomas J. Long School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is accredited for pharmacists for a maximum of 15 hours of continuing education credit (1.5 CEU), all application-based and are numbered 0006-0000-21-001-L08-P, 0006-0000-21-002-L01-P, 0006-0000-21-003-L06-P, 006-0000-21-004-L01-P, 0006-0000-21-005-L03-P, 0006-0000-21-006-L03-P, 0006-0000-21-012-L05-P, 0006-0000-21-007-L01-P, 0006-0000-21-008-L01-P, 006-0000-21-009-L01-P, 0006-0000-21-010-L01-P, 0006-0000-21-011-L01-P.

Program Requirements

To receive continuing education credit for each session in this program, pharmacists must complete a registration form that includes their individual NABP e-profile ID number and birth date, attend each session in full, complete and turn in an evaluation form for each session that includes a proof of attendance code. In addition, attendees will need to complete and turn in an overall program evaluation. Statements of credit will be uploaded to participant NABP e-profiles via CPE Monitor within 30 days of completion of the program. Paper statements will not be mailed. These are ongoing programs with an initial release date of 04.17.2021.

Program Sponsorship: None

TIME	SESSION	SPEAKER
10-11a.m.	<p>Updates in Chronic Pain Management</p> <p>0006-0000-21-001-L08-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. Describe the biopsychosocial model for the treatment of chronic pain. 2. List non-opioid medications, their mechanisms of action, and their indications for the treatment of pain. 3. Identify risks associated with chronic opioid use. 4. Apply the biopsychosocial approach to a chronic pain patient case. 	<p>Elizabeth Son, PharmD, PhD</p> <p>Pain Management Clinical Pharmacy Specialist, San Francisco VA Health Care System</p>
11a.m. - 12p.m.	<p>Multiple Sclerosis Management and Treatment</p> <p>0006-0000-21-002-L01-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. Describe the acute, long-term and symptomatic pharmacologic treatment of multiple sclerosis. 2. Delineate the efficacy, side effects and monitoring required for select multiple sclerosis therapies. 3. Apply the appropriate treatment plan in multiple sclerosis patient cases. 	<p>Elina Melamed, MD</p> <p>Staff Physician, Department of Neurology, VA Northern California Health Care System</p>
12 - 1p.m.	Break	
1 - 2p.m.	<p>Immunization Updates for Pediatric Patients</p> <p>0006-0000-21-003-L06-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. List the immunizations that are utilized in the pediatric population. 2. Analyze a pediatric patient case to determine immunization needs. 3. Identify which pediatric immunizations are live or inactivated to determine vaccine timing. 4. Describe newer ACIP recommendations for pediatric patients. 	<p>Veronica T. Bandy, PharmD, MS, FCPA, FCSHP, BCACP</p> <p>Clinical Professor, Sacramento Regional Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific</p>
2 - 3p.m.	<p>New Drugs in Select Gastrointestinal Disorders</p> <p>006-0000-21-004-L01-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. Discuss broadly the clinical presentation and diagnostic criteria related to irritable bowel disease (IBS) and inflammatory bowel disease (IBD). 2. Identify the new drugs which have been approved for IBS and IBD. 3. Discuss the mechanism of action, adverse drug reactions, and monitoring parameters associated with each new drug. 4. Discuss the clinical role and place in therapy of new drugs approved for IBS and IBD. 	<p>Deepti Vyas, PharmD</p> <p>Associate Professor, Director of Interprofessional Education and Instructional Design, Thomas J. Long School of Pharmacy, University of the Pacific</p>

TIME	SESSION	SPEAKER
9 - 10:30a.m.	<p>2021 New Pharmacy Laws Update</p> <p>0006-0000-21-005-L03-P 0.15 CEUs</p> <ol style="list-style-type: none"> 1. Describe the changes in State and Federal laws for 2021. 2. Explain the overarching trends in the regulatory climate for California pharmacists. 3. Summarize new standards of practices in pharmacy. 4. Identify resources for staying current on changing regulatory issues. 5. Evaluate the role of CURES for pharmacists in meeting their corresponding responsibility. 	<p>Tony J. Park, PharmD, JD</p> <p>Principal Attorney at CPL-California Pharmacy Lawyers; General Counsel for California Pharmacists Association; Legal Counsel for California Korean-American Pharmacists Association; Pharmacy Law and Ethics Professor, Western University, University of the Pacific, and Chapman University</p>
10:30 - 10:45a.m.	Break	
10:45a.m. - 12:15p.m.	<p>How the Government Wants Pharmacists to Decline Controlled Substance Prescriptions</p> <p>0006-0000-21-006-L03-P 0.15 CEUs</p> <ol style="list-style-type: none"> 1. Outline controlled substance enforcement trends by government agencies. 2. Construct a risk mitigation and compliance strategy. 3. Scrutinize common pharmacy practices for controlled substance dispensing. 4. Dispel common myths and misunderstandings regarding government enforcement of controlled substance prescriptions. 5. Understand how to lawfully decline controlled substance prescriptions to seemingly legitimate patients. 	<p>Tony J. Park, PharmD, JD</p> <p>Principal Attorney at CPL-California Pharmacy Lawyers; General Counsel for California Pharmacists Association; Legal Counsel for California Korean-American Pharmacists Association; Pharmacy Law and Ethics Professor, Western University, University of the Pacific, and Chapman University</p>
12:15 - 1:15p.m.	Break	
1:15 - 2:15p.m.	<p>BEERS Criteria in Clinical Practice</p> <p>0006-0000-21-012-L05-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. Identify three drug therapy changes in the recently revised BEERS Criteria. 2. Cite two significant additions or deletions to the newest BEERS Criteria. 3. Describe the Delphi process. 4. Name three medications usually best avoided for elders. 	<p>Lee Meyer, PharmD, BCGP, FASCP, FCPHA</p> <p>Principal Owner, M2: Pharmacist Service</p>

TIME	SESSION	SPEAKER
10 - 11:30a.m.	<p>Migraine Headaches: Update on the Pathophysiology, Clinical Presentation, Management and the Role of the Pharmacist</p> <p>0006-0000-21-007-L01-P 0.15 CEUs</p> <ol style="list-style-type: none"> 1. Describe the pathophysiological mechanisms and the clinical signs and symptoms of migraine. 2. Recognize medication-over-use-headache (MOH) and the criteria that supports its clinical diagnosis. 3. List some non-pharmacological interventions available for the management of migraine. 4. List the commonly used and recently approved abortive (acute) and preventative (prophylactic) medications and their role in the management of migraine headache. 5. Define the role of the pharmacist in the management of migraine headaches. 6. Apply the presented migraine guidelines to a patient case to make an appropriate recommendation. 	<p>George DeMaagd, PharmD, BCPS</p> <p>Professor of Pharmacy and Associate Dean of Academic Administration, Union University College of Pharmacy</p>
11:30a.m. - 12:30p.m.	Break	
12:30 - 2p.m.	<p>Current Advances in Depression Treatment</p> <p>0006-0000-21-008-L01-P 0.15 CEUs</p> <ol style="list-style-type: none"> 1. Review current strategies for the treatment of depression. 2. Examine common errors in the diagnosis of depression. 3. Present the new mechanism of action for medications utilizing the glutamate system. 4. Discuss current strategies and new medication for postpartum depression. 5. Compare and contrast updated guidelines for child and adolescent depression to past guidelines. 6. Apply the information regarding esketamine nasal spray to a patient case. 	<p>Kimberly A. Hoffmann PharmD, APh, BCPP, BCGP</p> <p>Clinical Professor and Bakersfield Regional Coordinator, Thomas J. Long School of Pharmacy, University of the Pacific</p>
2 - 3p.m.	<p>Medical Cannabis - What Pharmacists Want to Know</p> <p>006-0000-21-009-L01-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. Describe the basic pharmacology and potential therapeutic uses of medical cannabis. 2. List administration methods, side effects and patient safety issues with medical cannabis. 3. Discuss essential patient counseling points for the safe use of cannabis products. 4. Review legal considerations regarding the use of medical cannabis. 	<p>Deborah Yurovich-Berlekamp, PharmD, BCPS</p> <p>Assistant Professor of Pharmacy Practice, The University of Findlay College of Pharmacy</p>

TIME	SESSION	SPEAKER
10a.m. - 12p.m.	<p>Review of the Top Papers in Infectious Diseases from 2019-2020</p> <p>0006-0000-21-010-L01-P 0.2 CEUs</p> <ol style="list-style-type: none"> 1. Review the importance of staying up to date with the Infectious Diseases literature. 2. Discuss the most relevant articles published in the field of Infectious Diseases in 2019-2020. 3. Apply the literature to the changing practice of Infectious Diseases. 4. Discern the potential weaknesses of the papers published. 5. Discern the practice areas where there continues to be controversy in ID practice. 6. Summarize the most important changes in ID practice. 	<p>Hien H. Nguyen, MD, MAS</p> <p>Section Chief, Infectious Diseases, VA Northern California Health Care System; Professor of Medicine and Vice Chief, Division of Infectious Diseases, UC Davis Health</p>
12 - 1p.m.	Break	
1 - 2p.m.	<p>Surviving and Thriving with ADHD</p> <p>0006-0000-21-011-L01-P 0.1 CEU</p> <ol style="list-style-type: none"> 1. Discuss the age-specific treatment goals and recommendations for children and adults with ADHD. 2. Provide case examples whereby certain stimulant formulations may be more advantageous in a certain age or patient population. 3. Compare stimulant treatments with each other and with nonstimulants regarding efficacy, formulations, and side effects. 4. Counsel patients, parents, and caregivers on managing common side effects of ADHD medications. 5. Discuss the potential long-term and rare side effects of stimulants. 	<p>Julie Ann Dopheide, PharmD, BCPP, FASHP</p> <p>Professor of Clinical Pharmacy, Psychiatry and the Behavioral Sciences, University of Southern California School of Pharmacy and Keck School of Medicine; PGY2 Psychiatric Pharmacy Residency Program Director</p>
<p>In accordance with ACPE policies, all speakers were required to complete a "Declaration of Disclosure-Conflict of Interest Statement" prior to this educational activity. All have indicated they either have no relationship to disclose relating to the subject matter of their presentation or any conflicts were resolved using industry standard best practices. Please refer to each session's materials for conflict disclosures.</p>		

Updates in Chronic Pain Management

Since the recognition of the opioid crisis and development of guidelines de-emphasizing the use of opioid therapy to treat chronic pain, chronic pain management has evolved from a primarily biomedical to a biopsychosocial approach. This presentation will review the importance of a multimodal approach to pain and review non-opioid pain medications and their role in pain management.

Multiple Sclerosis Management and Treatment

To understand the new drugs in the pipeline: ozanimod and ublituximab.

Medical Cannabis - What Pharmacists Want to Know

The public is looking for answers regarding the legitimacy of cannabis use in medicine. There is a possibility that cannabis can potentially fill unmet needs in medicine, but there are many questions about legal issues and benefit versus risks. Patients and medical professionals expect pharmacists to provide these answers, but quality evidence and education are needed.

Immunization Updates for Pediatric Patients

To understand the pediatric immunization updates.

New Drugs in Select Gastrointestinal Disorders

There has been a slew of new drugs which are distinct in their mechanism of action and monitoring needs.

2021 New Pharmacy Laws Update

New pharmacy laws make it important for pharmacists to understand how it impacts the regulations and guidelines of medications and pharmacy services.

How the Government Wants Pharmacists to Decline Controlled Substance Prescriptions

To understand the new laws related to controlled substance prescriptions are critical.

BEERS Criteria in Clinical Practice

With an increasing elder population, it is important to understand the medication list and drug therapies. More importantly, how to screen for and assess potentially inappropriate drugs to prevent adverse effects, hospitalization and even death.

Migraine Headaches: Update on the Pathophysiology, Clinical Presentation, Management and the Role of the Pharmacist

The treatment of migraine has changed significantly over the past two years with the availability of new migraine specific abortive and preventive medications. In addition, the approval of non-pharmacological treatment options, including FDA approved neuromodulation devices.

Current Advances in Depression Treatment

A new medication, esketamine was developed and is now available. This medication is the first of many pharmacological treatments under development that are involved with the glutamate system and utilize the NMDA receptor in the body. It has been many years since a new class of antidepressant medications has been developed. This mechanism of action will be presented and a forecast of other new medications will be discussed in this talk. A new medication for postpartum depression will also be covered. Current strategies for treating depression including a close examination of the type of depressive disease will be examined as a misdiagnosis of unipolar depression is often made in patients. This includes the misuse of antidepressants in patients with Borderline Personality Disorder. There will also be a discussion of the updated guidelines for depression in children and adolescent patients.

Review of the Top Papers in Infectious Diseases from 2019-2020

The practice of Infectious Diseases changes rapidly but there is a known gap between new knowledge and the application of knowledge in practice. This program will highlight the most pertinent changes in Infectious Diseases by reviewing the most pertinent papers over the past two years.

Surviving and Thriving with ADHD

There has been an increase in prescription medications, mainly stimulants, for the treatment of attention deficit hyperactivity disorder (ADHD) along with an explosion of new formulations. Some new formulations last up to 16 hours and one new formulation is given at bedtime in contrast to most stimulants administered in the morning. Due to the increase in new stimulant formulations and potentially increased prescribing, pharmacists need to know the place in therapy of these new agents.



pharmacy.pacific.edu

UNIVERSITY OF THE
PACIFIC

Thomas J. Long
School of Pharmacy